MaxCyte, Inc.
MaxCyte, Inc. (MXCT) Financial Performance & Income Statement Overview
Analyze MaxCyte, Inc. (MXCT) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
MaxCyte, Inc. (MXCT) Income Statement & Financial Overview
Analyze MaxCyte, Inc.’s MXCT earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $10.39M | $8.69M | $8.16M | $10.43M |
| Cost of Revenue | $1.50M | $2.28M | $1.93M | $2.52M |
| Gross Profit | $8.89M | $6.41M | $6.24M | $7.91M |
| Gross Profit Ratio | $0.86 | $0.74 | $0.76 | $0.76 |
| R&D Expenses | $5.90M | $4.61M | $5.32M | $5.62M |
| SG&A Expenses | $14.22M | $13.68M | $13.95M | $14.23M |
| Operating Expenses | $20.13M | $19.31M | $20.29M | $19.85M |
| Total Costs & Expenses | $21.62M | $18.53M | $22.22M | $22.37M |
| Interest Income | $2.03M | $2.30M | $2.50M | $2.59M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $1.06M | $1.53M | $1.07M | $1.08M |
| EBITDA | -$10.17M | -$11.37M | -$12.99M | -$10.89M |
| EBITDA Ratio | -$0.98 | -$1.31 | -$1.59 | -$1.04 |
| Operating Income | -$11.23M | -$12.90M | -$14.05M | -$11.94M |
| Operating Income Ratio | -$1.08 | -$1.48 | -$1.72 | -$1.14 |
| Other Income/Expenses (Net) | $973000.00 | $2.30M | $2.50M | $2.59M |
| Income Before Tax | -$10.26M | -$10.60M | -$11.56M | -$9.38M |
| Income Before Tax Ratio | -$0.99 | -$1.22 | -$1.42 | -$0.90 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$10.26M | -$10.60M | -$11.56M | -$9.38M |
| Net Income Ratio | -$0.99 | -$1.22 | -$1.42 | -$0.90 |
| EPS | -$0.10 | -$0.10 | -$0.11 | -$0.09 |
| Diluted EPS | -$0.10 | -$0.10 | -$0.11 | -$0.09 |
| Weighted Avg Shares Outstanding | $105.95M | $104.85M | $105.11M | $104.64M |
| Weighted Avg Shares Outstanding (Diluted) | $105.95M | $104.85M | $105.11M | $104.64M |
Over the past four quarters, MaxCyte, Inc. demonstrated steady revenue growth, increasing from $10.43M in Q2 2024 to $10.39M in Q1 2025. Operating income reached -$11.23M in Q1 2025, maintaining a consistent -108% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$10.17M, reflecting operational efficiency. Net income rose to -$10.26M, with EPS at -$0.10. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan